Identity
HGNC
LOCATION
19q13.33
LOCUSID
ALIAS
GP52-40,TSPAN26
FUSION GENES
Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 951
MIM: 151523
HGNC: 1666
Ensembl: ENSG00000104894
Variants:
dbSNP: 951
ClinVar: 951
TCGA: ENSG00000104894
COSMIC: CD37
RNA/Proteins
Expression (GTEx)
Pathways
| Pathway | Source | External ID |
|---|---|---|
| Hematopoietic cell lineage | KEGG | ko04640 |
| Hematopoietic cell lineage | KEGG | hsa04640 |
Protein levels (Protein atlas)
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 35171311 | 2022 | CD37 expression in follicular lymphoma. | 3 |
| 35171311 | 2022 | CD37 expression in follicular lymphoma. | 3 |
| 32400873 | 2020 | CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. | 5 |
| 32400873 | 2020 | CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. | 5 |
| 30854931 | 2019 | Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. | 8 |
| 31089249 | 2019 | Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. | 14 |
| 31366619 | 2019 | High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. | 9 |
| 30854931 | 2019 | Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. | 8 |
| 31089249 | 2019 | Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. | 14 |
| 31366619 | 2019 | High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. | 9 |
| 30089630 | 2018 | Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. | 73 |
| 30185523 | 2018 | C-type lectin-like receptor 2 (CLEC-2)-dependent dendritic cell migration is controlled by tetraspanin CD37. | 9 |
| 30089630 | 2018 | Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. | 73 |
| 30185523 | 2018 | C-type lectin-like receptor 2 (CLEC-2)-dependent dendritic cell migration is controlled by tetraspanin CD37. | 9 |
| 27760757 | 2016 | Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. | 37 |
Citation
Dessen P
CD37 (CD37 molecule)
Atlas Genet Cytogenet Oncol Haematol. 2003-11-01
Online version: http://atlasgeneticsoncology.org/gene/977/cd37-(cd37-molecule)
